Even after years of work, courts still have a long way to go: 63% of cases in Superior Courts and Municipal Courts still need ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

drug prices, and what’s ahead for Johnson & Johnson. This interview has been condensed and edited for clarity. You've had some structural changes and spun out the consumer business. Has that ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Patients who experience musculoskeletal pain have many pharmaceutical options for relief — unless they also suffer from ...